Phibro Animal Health (NASDAQ:PAHC) Updates FY 2025 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.340-1.480 for the period, compared to the consensus earnings per share estimate of 1.550. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.2 billion.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on PAHC shares. JPMorgan Chase & Co. started coverage on Phibro Animal Health in a research note on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price on the stock. Bank of America lifted their target price on Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research note on Friday, August 30th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.00.

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC traded up $0.35 during midday trading on Friday, hitting $23.85. 203,227 shares of the company’s stock were exchanged, compared to its average volume of 158,175. Phibro Animal Health has a 12-month low of $9.40 and a 12-month high of $25.11. The company has a current ratio of 2.94, a quick ratio of 1.64 and a debt-to-equity ratio of 1.79. The company has a market cap of $966.00 million, a price-to-earnings ratio of 55.47, a PEG ratio of 0.57 and a beta of 0.51. The business’s fifty day moving average price is $22.37 and its two-hundred day moving average price is $19.38.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.07. Phibro Animal Health had a return on equity of 21.44% and a net margin of 1.67%. The firm had revenue of $273.16 million during the quarter, compared to the consensus estimate of $262.44 million. As a group, research analysts forecast that Phibro Animal Health will post 1.57 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Wednesday, November 27th will be paid a $0.12 dividend. The ex-dividend date is Wednesday, November 27th. This represents a $0.48 annualized dividend and a yield of 2.01%. Phibro Animal Health’s payout ratio is 111.63%.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, Director E Thomas Corcoran acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were bought at an average cost of $20.02 per share, with a total value of $100,100.00. Following the completion of the transaction, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $500,500. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 50.07% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.